[{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"CAR-NK cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Sofinnova Partners"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Expands Collaboration for CAR-NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ University of Minnesota","highestDevelopmentStatusID":"2","companyTruncated":"Catamaran Bio \/ University of Minnesota"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT\u2011179, a HER2-targeted Allogeneic CAR-NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR\u2011NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"MaxCyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Catamaran Bio"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"OmniaBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Selects Omniabio As Partner To Develop And Manufacture Allogeneic CAR-NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Catamaran Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Catamaran Bio

Catamaran Bio
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

02

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

03

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

04

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

05

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

06

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

07

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

08

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

09

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed

10

Catamaran Bio

U.S.A

Discovery on Target

Not Confirmed